Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

PEDIAZOLE

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

Standard Dose
EQ 200MG BASE/5ML;EQ 600MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PEDIAZOLE is listed in Drugs@FDA under application 050529 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL Form and strength GRANULE;ORAL - EQ 200MG BASE/5ML;EQ 600MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ROSS LABS Submission history Latest submission status date: 2004-02-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview PEDIAZOLE is listed in Drugs@FDA under application 050529 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL Form and strength GRANULE;ORAL - EQ 200MG BASE/5ML;EQ 600MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ROSS LABS Submission history Latest submission status date: 2004-02-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
PEDIAZOLE (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL) | Drug Monograph | MedicHelpline